glp-1 and Glucagon-like peptide-1 PDB-101: Molecule of the Month:

In 2021, the FDA approved Novo Nordisks application to market a GLP-1 drug for weight loss under the brand name Wegovy

[DOI] [PubMed] [Google Scholar] 113.Wang X, et al

& Livak, K

Active Ingredients: TB-500 10 mg BPC-157 10 mg GHK-Cu 50 mg KPV 10 mg Inactive Ingredients: Lyophilized peptide blend without preservatives KLOW vial (80 mg total peptide content) Antibacterial Water (for reconstitution) Test Certificate (for quality verification) Chemical Description: KLOW is a composite research formulation combining multiple synthetic peptides commonly studied for tissue repair, inflammatory signaling, and regenerative pathways

This is an oral compound with a completely distinct mechanism from any GLP-1 receptor agonist.